Also, considering the previous chapter of the current review, an important therapeutic strategy is represented by the combination of an HMA and an HDACi, which has been shown to increase the interaction between KMT2D and PU.1, leading to an inhibition of pERK, which is known to be upregulated in PTCL [118,119]. Here, KMT2D is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.